index kit a d (Illumina Inc)
97
Structured Review
Illumina Inc
index kit a d
Index Kit A D, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 97/100, based on 440 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statistics+data+analysis+version+mp+13+1+programs/Nextera+DNA+CD+Indexes/pm36827295-91-6-9
Average 97 stars, based on 440 article reviews
Index Kit A D, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 97/100, based on 440 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statistics+data+analysis+version+mp+13+1+programs/Nextera+DNA+CD+Indexes/pm36827295-91-6-9
Average 97 stars, based on 440 article reviews
index kit a d - by Bioz Stars,
2026-11
97/100 stars
Images
Related Articles
Purification:Article Title: Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD. Article Snippet: Background A deeper understanding of the relationship between dysbiotic gut microbiota and liver tissue-level molecular and histopathological phenotypes in metabolic dysfunction-associated steatotic liver disease (MASLD) remains needed.. We aimed to characterize the associations between gut microbial metabolic functions and treatment responses in participants with MASLD.. Methods We performed a prespecified sub-analysis of a randomized controlled trial comparing the sodium–glucose cotransporter 2 inhibitor (SGLT2i) tofogliflozin and the sulfonylurea (SU) glimepiride in participants with MASLD and type 2 diabetes (ClinicalTrials.gov NCT02649465). Polymerase Chain Reaction:Article Title: Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD. Article Snippet: Background A deeper understanding of the relationship between dysbiotic gut microbiota and liver tissue-level molecular and histopathological phenotypes in metabolic dysfunction-associated steatotic liver disease (MASLD) remains needed.. We aimed to characterize the associations between gut microbial metabolic functions and treatment responses in participants with MASLD.. Methods We performed a prespecified sub-analysis of a randomized controlled trial comparing the sodium–glucose cotransporter 2 inhibitor (SGLT2i) tofogliflozin and the sulfonylurea (SU) glimepiride in participants with MASLD and type 2 diabetes (ClinicalTrials.gov NCT02649465). Incubation:Article Title: Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD. Article Snippet: Background A deeper understanding of the relationship between dysbiotic gut microbiota and liver tissue-level molecular and histopathological phenotypes in metabolic dysfunction-associated steatotic liver disease (MASLD) remains needed.. We aimed to characterize the associations between gut microbial metabolic functions and treatment responses in participants with MASLD.. Methods We performed a prespecified sub-analysis of a randomized controlled trial comparing the sodium–glucose cotransporter 2 inhibitor (SGLT2i) tofogliflozin and the sulfonylurea (SU) glimepiride in participants with MASLD and type 2 diabetes (ClinicalTrials.gov NCT02649465). Amplification:Article Title: Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD. Article Snippet: Background A deeper understanding of the relationship between dysbiotic gut microbiota and liver tissue-level molecular and histopathological phenotypes in metabolic dysfunction-associated steatotic liver disease (MASLD) remains needed.. We aimed to characterize the associations between gut microbial metabolic functions and treatment responses in participants with MASLD.. Methods We performed a prespecified sub-analysis of a randomized controlled trial comparing the sodium–glucose cotransporter 2 inhibitor (SGLT2i) tofogliflozin and the sulfonylurea (SU) glimepiride in participants with MASLD and type 2 diabetes (ClinicalTrials.gov NCT02649465). Whole Complete genome sequencing:Article Title: Genomic Insights into Ciprofloxacin-Resistant Enteropathogenic Escherichia coli ST752 in Republic of Korea: A One Health Perspective on Its Emergence and Transmission. Article Snippet: Genomic DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Germantown, MD, USA) according to the manufacturer’s instructions. .. Index-tagged paired-end Illumina sequencing libraries were prepared using Article Title: Genomic Insights into Ciprofloxacin-Resistant Enteropathogenic Escherichia coli ST752 in Republic of Korea: A One Health Perspective on Its Emergence and Transmission Article Snippet: Genomic DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Germantown, MD, USA) according to the manufacturer’s instructions. .. Index-tagged paired-end Illumina sequencing libraries were prepared using other:Article Title: Complex HBB gene editing outcomes revealed by a fluorescent reporter cell model Article Snippet: A second PCR (PCR2) was performed to append dual-index barcodes and |